IP Library Granted Patent US 7,115,606
Granted Patent B2
US 7,115,606 · App. 10/863,770 · Granted Oct 3, 2006

Method of treating lower urinary tract disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,115,606
App. No.
10/863,770
Granted
Oct 3, 2006
Kind
B2
Abstract

The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT 3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising coadministering to said subject a first amount of a 5-HT 3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount.

Claims (18)

1. A method for treating overactive bladder without involuntary loss of urine comprising administering a therapeutically effective amount of a compound of formula II:

or a pharmaceutically acceptable salt thereof to a human subject in need thereof.

2. The method of claim 1 , wherein said administering is oral.

3. The method of claim 1 , wherein said administering is on an as-needed basis.

4. The method of claim 1 , wherein said therapeutically effective amount is from about 0.001 to about 1000 mg per day.

5. The method of claim 1 , wherein said therapeutically effective amount is from about 0.05 to about 500 mg per day.

6. The method of claim 1 , wherein said therapeutically effective amount is from about 0.03 to about 300 mg per day.

7. The method of claim 1 , wherein said therapeutically effective amount is from about 0.02 to about 200 mg per day.

8. The method of claim 1 , wherein said therapeutically effective amount is from about 0.1 to about 50 mg per day.

9. A method for treating at least one symptom of overactive bladder without involuntary loss of urine, wherein the symptom is selected from the group consisting of urinary frequency and urinary urgency, comprising administering a therapeutically effective amount of a compound of formula II:

or a pharmaceutically acceptable salt thereof to a human subject in need thereof.

10. The method of claim 9 , wherein said administering is oral.

11. The method of claim 9 , wherein said administering is on an as-needed basis.

12. The method of claim 9 , wherein said therapeutically effective amount is from about 0.001 to about 1000 mg per day.

13. The method of claim 9 , wherein said therapeutically effective amount is from about 0.05 to about 500 mg per day.

14. The method of claim 9 , wherein said therapeutically effective amount is from about 0.03 to about 300 mg per day.

15. The method of claim 9 , wherein said therapeutically effective amount is from about 0.02 to about 200 mg per day.

16. The method of claim 9 , wherein said therapeutically effective amount is from about 0.1 to about 50 mg per day.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2010
From: DYNOGEN PHARMACEUTICALS, INC.
To: EDUSA PHARMACEUTICALS, INC.
Reel/Frame 024879/0568 →
SECURITY AGREEMENT Recorded Jan 3, 2008
From: DYNOGEN PHARMACEUTICALS, INC.
To: ARACHNOVA THERAPEUTICS LIMITED
Reel/Frame 020309/0537 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2007
From: LANDAU, STEVEN B.; MILLER, CHERYL L.; FRASER, MATTHEW O.
To: DYNOGEN PHARMACEUTICALS, INC.
Reel/Frame 020004/0355 →